CryoPort (NASDAQ:CYRX) Hits New 12-Month High – Should You Buy?

CryoPort, Inc. (NASDAQ:CYRX) shares hit a new 52-week high during mid-day trading on Friday. The stock traded as high as $18.06 and last traded at $17.80, with a volume of 93747 shares changing hands. The stock had previously closed at $17.36.

Analyst Ratings Changes

A number of analysts recently commented on the company. Needham & Company LLC lifted their price objective on CryoPort from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Roth Capital restated a “buy” rating and set a $21.00 target price on shares of CryoPort in a research report on Friday, August 7th. Guggenheim raised their target price on shares of CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Thursday. BTIG Research reiterated a “buy” rating and set a $25.00 price target on shares of CryoPort in a research report on Friday, September 18th. Finally, Jefferies Financial Group set a $13.50 price target on shares of CryoPort in a research note on Monday, June 8th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.38.

CryoPort Price Performance

The business has a 50 day moving average of $16.01 and a 200 day moving average of $13.95. The firm has a market capitalization of $888.40 million, a price-to-earnings ratio of -19.52 and a beta of 1.95.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). CryoPort had a negative return on equity of 7.20% and a negative net margin of 20.05%.The company had revenue of $48.97 million for the quarter, compared to the consensus estimate of $48.18 million. As a group, equities analysts predict that CryoPort, Inc. will post -0.83 EPS for the current year.

Insider Activity

In related news, CEO Jerrell Shelton sold 28,800 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $14.91, for a total value of $429,408.00. Following the completion of the sale, the chief executive officer owned 1,201,814 shares in the company, valued at $17,919,046.74. This represents a 2.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AXQ Capital LP acquired a new stake in shares of CryoPort during the fourth quarter worth about $125,000. Highland Investment Advisors LLC acquired a new position in shares of CryoPort in the 2nd quarter valued at approximately $306,000. State of Wyoming grew its position in shares of CryoPort by 9.4% in the 1st quarter. State of Wyoming now owns 42,520 shares of the company’s stock valued at $352,000 after purchasing an additional 3,638 shares during the period. Kerrisdale Advisers LLC acquired a new stake in CryoPort during the 2nd quarter worth approximately $355,000. Finally, Quantinno Capital Management LP lifted its stake in CryoPort by 30.7% in the first quarter. Quantinno Capital Management LP now owns 43,966 shares of the company’s stock valued at $364,000 after buying an additional 10,337 shares in the last quarter. 92.90% of the stock is owned by institutional investors and hedge funds.

CryoPort Company Profile

Cryoport, Inc (NASDAQ: CYRX) provides temperature-controlled logistics and supply-chain solutions for the life sciences industry. The company supports the transportation, storage and management of sensitive biological materials, including cell and gene therapies, biologics, vaccines, clinical-trial materials and reproductive tissues.

Its offerings include specialized cryogenic and refrigerated shipping systems, monitoring and tracking technologies, logistics coordination, packaging and storage services, and related bioservices.